Evaluation of Neuroinflammation in Parkinson's Disease Using 18F-NOS PET/CT

Prior treatment

• Use of a CNS drug (prescription, over-the counter or recreational) within 30 days of screening, as assessed by review of medical history and concomitant medication review at screening (from medical record and/or self-report) that are deemed by a physician or investigator to have a potential influence on the binding of the applicable radiotracer.

Other illness

• History of epilepsy or seizure disorder as assessed by medical record review and/or self-report.
• History of head trauma that in the opinion of an investigator may interfere with the uptake of applicable radiotracer as assessed by medical record review and/or self- report.
• Current tobacco or nicotine dependence. History of greater than 5 pack years of smoking and less than 2 years since smoking cessation.
• Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician or investigator to be a condition that could compromise participant safety or successful participation in the study.
• History of first degree relative with Parkinson's Disease.

Other

• Females who are pregnant or breast feeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of child- bearing potential within one day of the PET/CT scan.
• At screening, the participant's weight is \> 350 lb.
• Subject reported claustrophobia that in the opinion of an investigator would interfere with acquisition of the structural MRI required for PET co-registration, and/or the PET scan itself.
• Self-reported current alcohol consumption of greater than or equal to 25 drinks per week.
• Inability to tolerate imaging procedures in the opinion of an investigator or treating physician.

• Participants will be 18-75 years of age.
• Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.
• Subjects with known neuropsychiatric disorder may be eligible if, in the opinion of an investigator, the psychiatric condition would not compromise subject safety or successful participation in the study.
• History of diagnosis of probable idiopathic PD derived from UK Brain Bank Diagnostic criteria(1) per neurologist review.
• Diagnosed with Parkinson's Disease at least 3 year prior to enrollment.
• Subjects will be selected who have the capacity to give their own informed consent, in the opinion of a neurology investigator.